KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Gains from Sales and Divestitures: 2021-2023

Historic Gains from Sales and Divestitures for Ginkgo Bioworks Holdings (DNA) over the last 1 years, with Jun 2023 value amounting to $27.2 million.

  • Ginkgo Bioworks Holdings' Gains from Sales and Divestitures rose 74.91% to $27.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $27.2 million, marking a year-over-year increase of 74.91%. This contributed to the annual value of $136.2 million for FY2022, which is 58.67% up from last year.
  • Ginkgo Bioworks Holdings' Gains from Sales and Divestitures amounted to $27.2 million in Q2 2023, which was up 130.20% from $11.8 million recorded in Q1 2023.
  • Ginkgo Bioworks Holdings' Gains from Sales and Divestitures' 5-year high stood at $136.2 million during Q4 2022, with a 5-year trough of $7.5 million in Q1 2022.
  • In the last 3 years, Ginkgo Bioworks Holdings' Gains from Sales and Divestitures had a median value of $23.5 million in 2022 and averaged $43.9 million.
  • Data for Ginkgo Bioworks Holdings' Gains from Sales and Divestitures shows a peak YoY skyrocketed of 74.91% (in 2023) over the last 5 years.
  • Ginkgo Bioworks Holdings' Gains from Sales and Divestitures (Quarterly) stood at $85.8 million in 2021, then soared by 58.67% to $136.2 million in 2022, then spiked by 74.91% to $27.2 million in 2023.
  • Its last three reported values are $27.2 million in Q2 2023, $11.8 million for Q1 2023, and $136.2 million during Q4 2022.